Gain Therapeutics Management
Management criteria checks 2/4
Gain Therapeutics' CEO is Gene Mack, appointed in Jun 2024, has a tenure of 1.83 years. total yearly compensation is $1.47M, comprised of 34.1% salary and 65.9% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $30.10K. The average tenure of the management team and the board of directors is 2.1 years and 5.3 years respectively.
Key information
Gene Mack
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 34.08% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.1yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Nov 07Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Dec 31Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$1m | US$500k | -US$20m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$21m |
| Dec 31 2024 | US$991k | US$271k | -US$20m |
Compensation vs Market: Gene's total compensation ($USD1.47M) is above average for companies of similar size in the US market ($USD622.00K).
Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.
CEO
Gene Mack (51 yo)
Mr. Gene Mack, M.B.A. is President, Chief Executive Officer & Director of Gain Therapeutics, Inc. from January 06, 2025 and was its Chief Financial Officer since April 8, 2024 until January 06, 2025 and wa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.2% $ 1.9m | |
| President | 1.8yrs | US$1.47m | 0.034% $ 30.1k | |
| Senior VP of Finance & Principal Financial Officer | 1.3yrs | US$345.07k | 0.074% $ 65.5k | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Senior Vice President of Research | 3.8yrs | no data | no data | |
| Chief Medical Officer | 2.1yrs | no data | no data |
Experienced Management: GANX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Founder | 9.3yrs | US$93.15k | 2.2% $ 1.9m | |
| President | 1.3yrs | US$1.47m | 0.034% $ 30.1k | |
| Independent Director | 5.3yrs | US$80.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$63.15k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$76.65k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$78.65k | 0.071% $ 62.7k | |
| Independent Director | 5.3yrs | US$68.15k | 0% $ 0 | |
| Member of Clinical Advisory Board | 1.3yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.3yrs | no data | no data | |
| Member of Clinical Advisory Board | 1.3yrs | no data | no data |
Experienced Board: GANX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/22 10:34 |
| End of Day Share Price | 2026/04/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gain Therapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |